A recent Vanderbilt poll found parents across the state reporting their children’s health care providers as the most trusted source for information about vaccines.

Vanderbilt University and Vanderbilt University Medical Center climbed seven spots in a survey by the National Science Foundation that measures annual research and development expenditures.

Vanderbilt's participation in vaccine effectiveness research continues to grow, with the Medical Center playing critical roles in several networks focused on surveillance of vaccine-preventable respiratory diseases.

Vanderbilt researchers have reported a major advance in understanding and potentially preventing dengue, a devastating, mosquito-borne tropical viral infection that is spreading across the globe.

The new bivalent mRNA COVID-19 booster vaccines that began being used in September are beneficial in preventing COVID-19-associated hospitalization in persons 65 and over.

Nine current faculty members of the Vanderbilt University School of Medicine have made this year’s list of scientists whose papers have been cited most frequently by other researchers.

On Thursday, Nov. 17, Mark Esser, PhD, vice president, Early Vaccines and Immune Therapies R&D at AstraZeneca, will discuss his company’s collaboration with Vanderbilt University Medical Center that led to development of the Evusheld antibody combo to prevent COVID-19 in high-risk individuals.